Trastuzumab
- Generic Name
- Trastuzumab
- Brand Names
- Herceptin, Herceptin Hylecta, Herzuma, Kanjinti, Ontruzant, Perjeta-Herceptin, Phesgo, Trazimera, Herwenda, Ogivri, Zercepac, Tuznue
- Drug Type
- Biotech
- Chemical Formula
- -
- CAS Number
- 180288-69-1
- Unique Ingredient Identifier
- P188ANX8CK
- Background
Produced in CHO cell cultures, trastuzumab is a recombinant IgG1 kappa, humanized monoclonal antibody that selectively binds with high affinity in a cell-based assay (Kd = 5 nM) to the extracellular domain of the human epidermal growth factor receptor protein (HER2). It is used as a treatment of human epidermal growth factor receptor (HER)-2+ metastatic bre...
- Indication
For the adjuvant treatment of HER2-overexpressing breast cancer, trastuzumab is indicated in several clinical settings: as part of a treatment regimen consisting of doxorubicin, cyclophosphamide, and either paclitaxel or docetaxel; as part of a treatment regimen with docetaxel and carboplatin; or as monotherapy following multi-modality anthracycline-based th...
- Associated Conditions
- Breast Cancer, Inflammatory Breast Cancer (IBC), Locally Advanced Breast Cancer (LABC), Metastatic Adenocarcinoma of the Gastroesophageal Junction, Metastatic Adenocarcinoma of the Stomach, Metastatic Breast Cancer, Metastatic Gastric Adenocarcinoma, Metastatic Gastroesophageal Junction Adenocarcinoma, Stage I Breast Cancer
- Associated Therapies
- -
Radiation Therapy With or Without Trastuzumab in Treating Women With Ductal Carcinoma In Situ Who Have Undergone Lumpectomy
- Conditions
- Interventions
- First Posted Date
- 2008-10-09
- Last Posted Date
- 2024-11-13
- Lead Sponsor
- National Cancer Institute (NCI)
- Target Recruit Count
- 2014
- Registration Number
- NCT00769379
- Locations
- 🇺🇸
Porter Adventist Hospital, Denver, Colorado, United States
🇺🇸Phoebe Putney Memorial Hospital, Albany, Georgia, United States
🇺🇸Hawaii Cancer Care Inc-Liliha, Honolulu, Hawaii, United States
Oral Deforolimus With Trastuzumab for Patients With HER2-positive Trastuzumab-Refractory Metastatic Breast Cancer (8669-009)
- Conditions
- Interventions
- First Posted Date
- 2008-08-18
- Last Posted Date
- 2015-08-27
- Lead Sponsor
- Merck Sharp & Dohme LLC
- Target Recruit Count
- 34
- Registration Number
- NCT00736970
Combination Therapy With MYOCET® (Doxorubicin HCL Liposome for Injection) in Participants With HER2-Positive Breast Cancer
- Conditions
- Interventions
- First Posted Date
- 2008-07-10
- Last Posted Date
- 2024-02-23
- Lead Sponsor
- Cephalon, Inc.
- Target Recruit Count
- 126
- Registration Number
- NCT00712881
- Locations
- 🇩🇪
Teva Investigational Site 30, Aachen, Germany
🇧🇪Teva Investigational Site 9, Brussels, Belgium
🇦🇹Teva Investigational Site 15, Wien, Austria
A Study to Determine the Activity of Caelyx With Trastuzumab and Docetaxel in the Treatment of Metastatic Breast Cancer (Study P03679)
- Conditions
- Interventions
- First Posted Date
- 2008-05-30
- Last Posted Date
- 2018-07-03
- Lead Sponsor
- Merck Sharp & Dohme LLC
- Target Recruit Count
- 27
- Registration Number
- NCT00687440
A Study of the Efficacy and Safety of Trastuzumab Emtansine (Trastuzumab-MCC-DM1) vs. Trastuzumab (Herceptin®) and Docetaxel (Taxotere®) in Patients With Metastatic HER2-positive Breast Cancer Who Have Not Received Prior Chemotherapy for Metastatic Disease
- Conditions
- Interventions
- First Posted Date
- 2008-05-16
- Last Posted Date
- 2014-01-09
- Lead Sponsor
- Hoffmann-La Roche
- Target Recruit Count
- 137
- Registration Number
- NCT00679341
Bevacizumab in Combination With Vinorelbine and Trastuzumab for HER2-Positive, Metastatic Breast Cancer
- Conditions
- Interventions
- First Posted Date
- 2008-05-02
- Last Posted Date
- 2013-05-13
- Lead Sponsor
- Harold J. Burstein, MD, PhD
- Target Recruit Count
- 29
- Registration Number
- NCT00670982
- Locations
- 🇺🇸
Hartford Hospital, Hartford, Connecticut, United States
🇺🇸Massachusetts General Hospital, Boston, Massachusetts, United States
🇺🇸Beth Israel Deaconess Medical Center, Boston, Massachusetts, United States
Trastuzumab Optimization Trial in Breast Cancer
- First Posted Date
- 2008-03-17
- Last Posted Date
- 2008-03-17
- Lead Sponsor
- Regione Lombardia
- Target Recruit Count
- 500
- Registration Number
- NCT00637325
- Locations
- 🇮🇹
Azienda Ospedaliera Busto Arsizio - Presidio ospedaliero Saronno, Saronno, Varese, Italy
🇮🇹Azienda Ospedaliera Sant' Anna, Como, Italy
🇮🇹Azienda Ospedaliero-Universitaria di Parma, Parma, Italy
Nanoparticle Albumin-Bound (Nab) Paclitaxel/Cyclophosphamide in Early-Stage Breast Cancer
- Conditions
- Interventions
- First Posted Date
- 2008-03-06
- Last Posted Date
- 2021-11-24
- Lead Sponsor
- SCRI Development Innovations, LLC
- Target Recruit Count
- 63
- Registration Number
- NCT00629499
- Locations
- 🇺🇸
Gulfcoast Oncology Associates, Saint Petersburg, Florida, United States
🇺🇸Watson Clinic Center for Cancer Care and Research, Lakeland, Florida, United States
🇺🇸Grand Rapids Clinical Oncology Program, Grand Rapids, Michigan, United States
BETH Study: Treatment of HER2 Positive Breast Cancer With Chemotherapy Plus Trastuzumab vs Chemotherapy Plus Trastuzumab Plus Bevacizumab
- Conditions
- Interventions
- First Posted Date
- 2008-02-29
- Last Posted Date
- 2020-09-10
- Lead Sponsor
- NSABP Foundation Inc
- Target Recruit Count
- 3509
- Registration Number
- NCT00625898
- Locations
- 🇺🇸
Peninsula Regional Oncology & Hematology, Salisbury, Maryland, United States
🇺🇸Associates in Oncology/Hematology, Rockville, Maryland, United States
🇺🇸The Office of Frederik Smith, Chevy Chase, Maryland, United States
Carboplatin+Nab-paclitaxel, Plus Trastuzumab (HER2+) or Bevacizumab (HER2-) in the Neoadjuvant Setting
- Conditions
- Interventions
- First Posted Date
- 2008-02-20
- Last Posted Date
- 2024-02-28
- Lead Sponsor
- University of California, Irvine
- Target Recruit Count
- 127
- Registration Number
- NCT00618657
- Locations
- 🇺🇸
Chao Family Comprehensive Cancer Center, Orange, California, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.